Related Experiment Videos
Intraocular pressure elevation after intravitreal triamcinolone acetonide injection
Jost B Jonas1, Robert F Degenring, Ingrid Kreissig
1Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University Heidelberg, Heidelberg, Germany. Jost.Jonas@augen.ma.uni-heidelberg.de
Ophthalmology
|April 6, 2005
Summary
Intravitreal triamcinolone acetonide injections can cause elevated intraocular pressure (IOP) in many patients, often resolving within 9 months. Younger age is linked to higher IOP after this treatment.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Intravitreal triamcinolone acetonide is used for various retinal conditions.
- Monitoring intraocular pressure (IOP) is crucial after treatment.
Purpose of the Study:
- To analyze IOP changes following intravitreal triamcinolone acetonide injections.
- To identify factors associated with IOP elevation.
Main Methods:
- Meta-analysis of existing data and case series.
- Included 272 patients (305 eyes) treated for conditions like AMD, DME, RVO, and uveitis.
- Follow-up averaged 10.4 months.
Main Results:
- 41.2% of patients experienced IOP > 21 mmHg.
- IOP elevation peaked within a week and normalized around 8-9 months post-injection.
- Younger age was significantly associated with increased IOP.
Conclusions:
- Intravitreal triamcinolone acetonide frequently causes transient ocular hypertension.
- Findings aid in risk-benefit assessments for this therapy.